Healthcare Biz Roundup: Complete Genomics Pops, Cardium Therapeutics Crashes
Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares jump up after the firm reports positive results for its Sapacitabine drug in a phase 2 trial on Myelodysplastic patients.
Valeant Pharmaceuticals (NYSE:VRX) snaps up Eyetech for an undisclosed upfront payment and potential future milestones. The deal is expected to be accretive to earnings immediately. Eyetech makes Macugen – a treatment for age-related macular degeneration.
Complete Genomics (NASDAQ:GNOM) shares pop on rumors the company was selected by the Mayo Clinic to provide outsourced whole human genome sequencing.
Chelsea Therapeutics (NASDAQ:CHTP) hits the wall after the firm says recent talks with the Food and Drug Administration raised questions about the risks of its Northera drug designed to improve symptoms of diseases such as Parkinson’s.
Cardium Therapeutics (AMEX:CXM) shares propel downward over 20% after the company announces that it will sell over 17 million shares of its common stock in a registered direct offering.
To contact the reporter on this story: Tanya Harding at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com